Fact Source: Financial Supervisory Service DART / 2026-02-05
Disclosure Type: Alteration of over 30% (15% for Large-scale Corporations) in Revenue or Profit/Loss Structure
💡 3-Second Summary
Driven by sustained global prescriptions of existing products, expanding sales of high-margin new pipelines, and the resolution of merger-related expenses, Celltrion recorded a historic performance with consolidated revenue of KRW 4.16 trillion and operating profit of KRW 1.17 trillion.
📊 1. [Summary of Key Disclosure Content and Major Figures]
- Reporting Period: Fiscal Year 2025 Consolidated Tentative Performance (Applicable as a Large-scale Corporation)
- Date of Board Resolution: February 5, 2026 (All 8 outside directors attended).
[Details of Fluctuations in Revenue and Profit/Loss Structure (Unit: KRW)]
- Revenue: 4,162,495,109,000 (Approx. KRW 4.16T)
- Increased by 605,191,555,000 (17.01%) from the previous fiscal year (3,557,303,554,000).
- Operating Profit: 1,168,471,346,000 (Approx. KRW 1.17T)
- Increased by 676,455,811,000 (137.49%) from the previous fiscal year (492,015,535,000).
- Profit Before Income Tax: 1,153,720,442,000 (Approx. KRW 1.15T)
- Increased by 577,603,631,000 (100.26%) from the previous fiscal year (576,116,811,000).
- Net Income: 1,031,483,789,000 (Approx. KRW 1.03T)
- Increased by 612,600,479,000 (146.25%) from the previous fiscal year (418,883,310,000).
[Major Financial Status (Unit: KRW)]
- Total Assets: 22,361,324,750,000 (Approx. KRW 22.36T)
- Total Liabilities: 5,008,794,931,000 (Approx. KRW 5.01T)
- Total Equity: 17,352,529,819,000 (Approx. KRW 17.35T)
- Share Capital: 239,361,656,000 (Approx. KRW 239.4B)
- Separate/Individual Revenue: 2,928,637,506,000 (Approx. KRW 2.93T)
- Capital Impairment Rate: N/A
[Primary Reasons for Revenue and Profit/Loss Fluctuations]
- Factors for Revenue Increase: Achieved maximum historical revenue due to the expansion of high-margin new product sales combined with sustained robust global prescriptions of existing key products.
- Factors for Profit Increase: Registered record-high operating profit due to a substantial improvement in the cost of goods sold (COGS) ratio—driven by the resolution of merger-related impacts, a higher proportion of high-margin product portfolios, and productivity enhancements—along with the mitigation of fixed selling, general, and administrative (SG&A) expenses supported by overall revenue growth.
📈 2. [Expert Perspective: What This Disclosure Means for Investors]
This financial restructuring disclosure serves as an official confirmation that Celltrion’s top-line growth and bottom-line expansion are structural, rather than transient adjustments. Securing record-high consolidated annual revenue of KRW 4.16T and pushing operating profits up by 137.49% to KRW 1.17T validates a fundamental strengthening of the company’s long-term earning power.
Significantly, the primary documents officially delineate the concrete drivers for these earnings expansions: the resolution of merger-related friction and a profound optimization of the cost structure. The strategic shift toward higher-value biosimilar products coupled with localized productivity enhancements successfully lowered the COGS ratio. Concurrently, the scale of top-line revenue growth helped dilute fixed SG&A cost weight, fostering a compounding margin expansion that drove net income past the KRW 1T threshold.
From a financial architecture perspective, while total liabilities increased, the robust consolidated capital base of KRW 17.35T indicates negligible liquidity risks. Meanwhile, parent-only separate revenue (KRW 2.93T) remains lower than the consolidated total, which may be a temporary artifact of downstream channel restructuring or internal trade adjustments with overseas distribution subsidiaries. Because this represents tentative internal bookkeeping prior to the completion of the external audit, these figures could undergo minor alterations upon the submission of the finalized audit report. Nevertheless, the underlying trajectory suggests a potential impact of long-term operational leverage improvement.
📝 Editor’s Comment (by K-STOCK Editor)
Celltrion has addressed the market’s primary concern regarding post-merger margin compression by delivering solid numerical proof of structural cost optimization. According to the disclosure, the resolution of merger-related administrative burdens and a strategic focus on high-margin product mixes have catalyzed this earnings boom. Securing over KRW 1 trillion in operating profit not only secures a reassuring fundamental baseline but also provides the capital flexibility required to execute the company’s broader shareholder value-up initiatives. Since these results remain tentative, market participants is likely to carefully cross-examine the finalized audited figures in the upcoming audit report to verify the precise long-term trajectory.
📢 Disclaimer and Source Information
Source: This content was newly structured and written based on official data submitted to the Financial Supervisory Service’s electronic disclosure system (DART).
Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
